[go: up one dir, main page]

MX2017003944A - Combinacion de un acido graso omega-3 y un inhibidor de sglt-2 para tratar enfermedades hepaticas. - Google Patents

Combinacion de un acido graso omega-3 y un inhibidor de sglt-2 para tratar enfermedades hepaticas.

Info

Publication number
MX2017003944A
MX2017003944A MX2017003944A MX2017003944A MX2017003944A MX 2017003944 A MX2017003944 A MX 2017003944A MX 2017003944 A MX2017003944 A MX 2017003944A MX 2017003944 A MX2017003944 A MX 2017003944A MX 2017003944 A MX2017003944 A MX 2017003944A
Authority
MX
Mexico
Prior art keywords
sglt
omega
liver
inhibitor
combination
Prior art date
Application number
MX2017003944A
Other languages
English (en)
Inventor
Erik Goeran Gannedahl Karl
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of MX2017003944A publication Critical patent/MX2017003944A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Emergency Medicine (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Se reclama un método para tratar NAFLD y/o NASH y composiciones adecuadas para llevar a cabo el método.
MX2017003944A 2014-09-25 2015-09-24 Combinacion de un acido graso omega-3 y un inhibidor de sglt-2 para tratar enfermedades hepaticas. MX2017003944A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462055055P 2014-09-25 2014-09-25
US201462075471P 2014-11-05 2014-11-05
PCT/EP2015/071962 WO2016046311A1 (en) 2014-09-25 2015-09-24 Combination of an omega-3 fatty acid and an sglt-2 inhibitor for treating diseases of the liver

Publications (1)

Publication Number Publication Date
MX2017003944A true MX2017003944A (es) 2017-06-26

Family

ID=54266538

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017003944A MX2017003944A (es) 2014-09-25 2015-09-24 Combinacion de un acido graso omega-3 y un inhibidor de sglt-2 para tratar enfermedades hepaticas.

Country Status (11)

Country Link
US (2) US9757404B2 (es)
EP (1) EP3197555A1 (es)
JP (2) JP2017528499A (es)
KR (1) KR20170049606A (es)
CN (1) CN106714840A (es)
AU (1) AU2015323779B2 (es)
CA (1) CA2961148A1 (es)
MX (1) MX2017003944A (es)
RU (1) RU2695652C2 (es)
TW (1) TW201632179A (es)
WO (1) WO2016046311A1 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6563376B2 (ja) * 2016-08-26 2019-08-21 合同会社カルナヘルスサポート 網膜症治療剤
ES3026786T3 (en) * 2017-01-11 2025-06-12 Kowa Co Pemafibrate in combination with a sglt2 inhibitor for the prophylactic or therapeutic treatment of liver diseases nonalcoholic fatty liver disease
ES2927019T3 (es) 2017-03-28 2022-11-02 Gilead Sciences Inc Combinaciones terapéuticas para el tratamiento de enfermedades hepáticas
CA3077273A1 (en) * 2017-10-06 2019-04-11 Gilead Sciences, Inc. Combination therapy comprising an acc inhibitor
CN109682909B (zh) * 2017-10-18 2020-11-10 中国科学院大连化学物理研究所 一种用于评价2型糖尿病的格列齐特适用性的血清组合标志物及其检测试剂盒
JPWO2019092770A1 (ja) 2017-11-07 2019-11-14 合同会社カルナヘルスサポート 網膜疾患治療剤
US11549878B2 (en) 2018-08-09 2023-01-10 Albireo Ab In vitro method for determining the adsorbing capacity of an insoluble adsorbant
US11918602B2 (en) 2018-08-10 2024-03-05 Simeon Investment, Inc. Methods for reducing cholesterol with superabsorbent materials
US11925660B2 (en) 2018-08-10 2024-03-12 Simeon Investment, Inc. Treatment for obesity with superabsorbent materials
US12285738B2 (en) 2018-08-10 2025-04-29 Simeon Investment, Inc. Modulation of glucose bioaccessibility with superabsorbent materials
CN112752582A (zh) * 2019-08-30 2021-05-04 阿斯利康(瑞典)有限公司 利用达格列净治疗射血分数降低的心力衰竭的方法
WO2022049168A1 (en) * 2020-09-04 2022-03-10 Dsm Ip Assets B.V. 17(s)-hdpa for metabolic-syndrome related disorders
KR20220122877A (ko) * 2021-02-26 2022-09-05 유한회사 한터 블랙커런트 열수 추출물을 포함하는 비알코올성 지방간 질환의 예방, 개선 또는 치료용 조성물

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PH12000002657B1 (en) 1999-10-12 2006-02-21 Bristol Myers Squibb Co C-aryl glucoside SGLT2 inhibitors
US6515117B2 (en) 1999-10-12 2003-02-04 Bristol-Myers Squibb Company C-aryl glucoside SGLT2 inhibitors and method
CA2572793C (en) 2004-07-21 2015-11-03 Kissei Pharmaceutical Co., Ltd. Progression inhibitor for disease attributed to abnormal accumulation of liver fat
US7919598B2 (en) 2006-06-28 2011-04-05 Bristol-Myers Squibb Company Crystal structures of SGLT2 inhibitors and processes for preparing same
JP5302900B2 (ja) * 2008-01-31 2013-10-02 アステラス製薬株式会社 脂肪性肝疾患の治療用医薬組成物
AU2010242498A1 (en) * 2009-05-01 2011-12-22 Micropharma Limited Bacterial compositions for prophylaxis and treatment of degenerative disease
ITMI20101666A1 (it) 2010-09-13 2012-03-14 Dmf Dietetic Metabolic Food S R L Composizione a base di acido docosaesaenoico (dha), nel trattamento della fibrosi cistica e della steatosi epatica non alcolica
CA2916208A1 (en) * 2012-06-17 2013-12-27 Matinas Biopharma, Inc. Omega-3 pentaenoic acid compositions and methods of use
CN102755350B (zh) 2012-08-01 2015-07-01 浙江金诺康生物制药有限公司 精制海狗油及其在制备治疗非酒精性脂肪肝药物中的应用
US20140187633A1 (en) 2012-12-31 2014-07-03 Amarin Pharmaceuticals Ireland Limited Methods of treating or preventing nonalcoholic steatohepatitis and/or primary biliary cirrhosis
AU2014230444B2 (en) * 2013-03-15 2018-05-17 Mochida Pharmaceutical Co., Ltd. Compositions and methods for treating non-alcoholic steatohepatitis

Also Published As

Publication number Publication date
AU2015323779B2 (en) 2018-08-09
AU2015323779A1 (en) 2017-03-16
CA2961148A1 (en) 2016-03-31
EP3197555A1 (en) 2017-08-02
CN106714840A (zh) 2017-05-24
WO2016046311A1 (en) 2016-03-31
RU2695652C2 (ru) 2019-07-25
US20160113953A1 (en) 2016-04-28
RU2017112149A (ru) 2018-10-25
US9757404B2 (en) 2017-09-12
JP2020147585A (ja) 2020-09-17
KR20170049606A (ko) 2017-05-10
JP2017528499A (ja) 2017-09-28
RU2017112149A3 (es) 2019-03-12
TW201632179A (zh) 2016-09-16
US20180021359A1 (en) 2018-01-25

Similar Documents

Publication Publication Date Title
MX2017003944A (es) Combinacion de un acido graso omega-3 y un inhibidor de sglt-2 para tratar enfermedades hepaticas.
IL287586A (en) Methods and preparations for enriching breeding products
IL263377A (en) A method for creating bacterial preparations
GB201706751D0 (en) Compositions and methods for treating inflamatory diseases
IL254282A0 (en) Methods for treating non-alcoholic fatty liver disease and/or lipid metabolism disorder
IL275002A (en) Fatty acid antecedents for the treatment of nonalcoholic fatty liver disease
HUE057327T2 (hu) Készítmények és eljárások HAO1 (hidroxisav-oxidáz-1 (glikolát-oxidáz)) gén expressziójának gátlására
PH12018500659A1 (en) Compounds effective in treating hepatotoxicity and fatty liver diseases and uses thereof
IL252138A0 (en) Nutrient fatty acid composition is optimized
EP3209298A4 (en) Compositions and methods for treating insomnia
MX2016012835A (es) Composiciones y metodos para tratar las espinillas.
EP3139928A4 (en) Anordrin compositions and methods for treating diseases
EP3132795A4 (en) Composition for preventing or treating fatty liver diseases
EP3110446A4 (en) Methods and compositions for treating siglec-8 associated diseases
IL259590A (en) Preparations and methods for manipulating plant growth
IL285900A (en) Phorbol ester preparations and methods for treating cytopenia or reducing its duration
SG11201702554QA (en) Compositions and methods for the treatment of multiple sclerosis
EP3653219A4 (en) COMPOSITION FOR THE TREATMENT OF HEPATIC STEATOSIS
EP3164132A4 (en) Methods and compositions for treating diseases and conditions
MX2018002936A (es) Metodos y composiciones inhibidoras de incrustacion.
EP3250037A4 (en) Compositions and methods for creating pancreatic cancer animal model
MX383947B (es) Composiciones de colágeno 7 y métodos para usar las mismas.
GB2549006B (en) Hybrid plant products from Theobroma species and methods of making the same
PL3233074T3 (pl) Leczenie niealkoholowych stłuszczeniowych chorób wątroby
IL252707B (en) Compositions and methods for treating diseases